CSIMarket

Codexis inc.  (CDXS)
Other Ticker:  
 
 
Price: $8.8400 $0.50 5.995%
Day's High: $8.945 Week Perf: 6.89 %
Day's Low: $ 8.31 30 Day Perf: -26.76 %
Volume (M): 759 52 Wk High: $ 42.01
Volume (M$): $ 6,705 52 Wk Avg: $21.00
Open: $8.41 52 Wk Low: $6.15



 Market Capitalization (Millions $) 577
 Shares Outstanding (Millions) 65
 Employees 106
 Revenues (TTM) (Millions $) 135
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 9

Codexis Inc.

We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which have been continuously improved over our fifteen year history, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers.
Many companies have historically used naturally occurring proteins to produce or enhance goods used in everyday life. Despite the growing number of commercial applications of naturally occurring proteins across many industries, the inherent limitations of naturally-occurring proteins frequently restrict their commercial use. Through the application of our proprietary CodeEvolver® protein engineering technology platform, we are able to engineer novel proteins to overcome these restrictions, thereby adding value or opening up new prospects for our potential clients’ products, processes or businesses. We have developed new proteins that are significantly more stable and/or active in our commercial applications than proteins derived from nature.

We are a pioneer in the harnessing of computational technologies to drive biology advancements. Over the last fifteen years, we have made substantial investments in the development of our CodeEvolver® protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants’ performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver® protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development which are all coordinated to create our novel protein innovations.

Our strategy is to grow our revenues, profits, and stockholder value by leveraging our CodeEvolver® protein engineering technology platform in the following ways:

Licensing our CodeEvolver® protein engineering technology platform. We intend to continue to pursue opportunities to license our CodeEvolver® protein engineering technology platform to third parties so they can create cost-saving protein catalyst solutions utilizing their own in-house protein engineering capability.

Growing our pharmaceutical protein catalysts business. We intend to continue to pursue opportunities in the pharmaceutical market to use our protein catalysis products and services to reduce the costs for manufacturing small molecule drugs. We intend to increase the number of pharmaceutical customers and processes that utilize and benefit from our novel, cost-saving protein catalyst solutions.

Growing our fine chemicals protein catalysts business. We intend to continue to pursue opportunities in the fine chemicals market to use protein catalysis products and services to reduce the costs for manufacturing in adjacent markets like food and food ingredients. We intend to increase the number of fine chemical customers and processes who utilize and benefit from our novel, cost-saving protein catalyst solutions.

Creating and advancing novel biotherapeutic drug candidates. We intend to continue to pursue opportunities to apply our protein engineering capabilities to the creation and development of novel biotherapeutic drug candidates, both in partnership with customers and as proprietary Codexis drug candidates. We intend to continue to advance our own novel enzyme biotherapeutic candidate for the potential treatment of phenylketonuria ("PKU") disease. We have also invested in research and development in an effort to generate additional early stage novel biotherapeutic candidates.

Developing high-performance enzymes for use in diagnostic applications. We intend to offer high-performance enzymes to customers using next generation sequencing (“NGS”) and polymerase chain reaction (“PCR/qPCR”) for in vitro molecular diagnosis applications.

Our pharmaceutical customers, which include a majority of the largest global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. Our CodeEvolver® protein engineering technology platform enables us to deliver solutions to our customers in this market by developing and delivering optimized protein catalysts that perform chemical transformations at a lower cost and improve the efficiency and productivity of manufacturing processes. We provide value throughout the pharmaceutical product lifecycle. Our products and services allow us to provide benefits to our pharmaceutical customers in a number of cost saving ways, including any - and sometimes all - of the following:
reducing the use of raw materials and reagents;
eliminating multiple steps in the manufacturing process;
improving purity, productivity and yield;
using water as a primary solvent;
eliminating hazardous inputs;
enabling the use of simple equipment and reducing the need for capital expenditure;
reducing energy requirements;
reducing the generation of chemical byproducts or waste; and
reducing the need for late-stage purifications.
Early in a pharmaceutical product’s lifecycle, pharmaceutical manufacturers can use our protein catalyst products and services to reduce manufacturing costs. If an innovator incorporates our products or processes into an approved product, we expect the innovator to continue to use our products or processes at least over the patent life of the marketed drug.
Pharmaceutical manufacturers can also use our products and services to reduce manufacturing costs after a product is launched. At this stage, changes in the manufacturing process originally approved by the drug regulator may require additional regulatory review. Typically, pharmaceutical companies will only seek regulatory approval for a manufacturing change if substantial cost savings are realizable. We believe that the cost savings associated with our products may lead our customers to change their manufacturing processes for approved products and, if necessary, seek regulatory approval of the new processes which incorporate our proteins. Moreover, we believe these cost savings are attractive to generics manufacturers, who compete primarily on price.
In addition, manufacturing processes that utilize our protein catalysts can frequently enable processes that are more sustainable and environmentally friendly compared to alternative, traditional manufacturing approaches. This has led Codexis to earn three US EPA Presidential Green Chemistry Challenge awards for improved pharmaceutical manufacturing processes over the last eleven years. All three of these awards were associated with blockbuster drug products.



   Company Address: 200 Penobscot Drive Redwood City 94063 CA
   Company Phone Number: 421-8100   Stock Exchange / Ticker: NASDAQ CDXS
   CDXS is expected to report next financial results on November 04, 2022.


Customers Net Income grew by CDXS's Customers Net Profit Margin grew to

12 %

22.69 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

Year to Date Decrease / Increase
     
BDX        4.14% 
BMRN        6.39% 
DD   -22.27%    
• View Complete Report
   



California Bancorp

EPS Trails Revenues

For the second quarter of 2022 company Revenues grew faster than eps, Revenue increased by 6.71% from the same quarter a year ago to $16.69 millions, while earnings grew modestly by 2 % to $0.51 per share.

Periphas Capital Partnering Corporation

Periphas Capital Partnering Corporation disclosed fiscal time-frame ending Jun 30 2022 operating profit of $0.228392 millions

Periphas Capital Partnering Corporation announced operating income of $0.228392 millions, in the fiscal time-frame ending Jun 30 2022, an advancement from the operating shortfall of $-0.356878 millions, recorded in the same quarter a year ago.

Willamette Valley Vineyards Inc.

Deficit Bigger Than a Year Ago, Sales Down Slightly

Weakening demand led to deficit in the second quarter of 2022, Sales fell by -2.78% to $8.70 millions and loss per share was at $-0.04 compared to $0.14 per share realized in quarter a year ago.

Mudrick Capital Acquisition Corporation Ii

EPS Soared by Mudrick Capital Acquisition Corporation Ii in the financial time-frame ending Jun 30 2022 statement

In the financial time-frame ending Jun 30 2022 Mudrick Capital Acquisition Corporation Ii earnings per share soared of $0.08 per share compared to $0.00 a year ago and profit plummeted by -61.9 % from $0.21 per share from the previous quarter.

Cova Acquisition Corp.

Cova Acquisition Corp declared second quarter of 2022 earnings season operating loss of $-3.181421 millions

In the second quarter of 2022 earnings season Cova Acquisition Corp increased losses of $-0.02 per share compared to $0.00 a year ago and eps fell from $0.18 per share from the previous quarter.






 

Codexis's Segments
 
 
• View Complete Report


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TDG's Profile

Stock Price

TDG's Financials

Business Description

Fundamentals

Charts & Quotes

TDG's News

Suppliers

TDG's Competitors

Customers & Markets

Economic Indicators

TDG's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071